Curiosity Delivers.

McGill bioethicists argue for stricter limits on first-in-human clinical trials

The standards for drugs entering first-in-human (FIH) clinical trials are too low, argues Associate Professor Dr. Jonathan Kimmelman and PhD candidate Carole Federico in McGill’s Biomedical Ethics Unit. In a commentary published online in Nature on Jan. 30, Kimmelman and Federico maintain that evidence for drug efficacy is not emphasized enough before FIH trials and call for… Keep Reading

The case for eradicating malaria with gene-editing technologies

What if we could rid the world of any species that we didn’t like: The annoying ones, the dangerous ones, and the disease-spreading ones? This seems like a tall order and one that carries a number of ethical quandaries. With the advent of CRISPR/Cas9 gene technologies, the once theoretical bioethics is now a real consideration… Keep Reading

Curiosity Delivers.
Go to Top